+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rare Autoinflammatory Diseases Drug Market - Global Forecast 2025-2030- Product Image
Rare Autoinflammatory Diseases Drug Market - Global Forecast 2025-2030- Product Image
Sale

Rare Autoinflammatory Diseases Drug Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6124268
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Rare autoinflammatory disorder therapeutics represent a complex and rapidly evolving market, shaped by innovations in diagnostics, personalized therapy approaches, and a dynamic regulatory landscape. Industry leaders, policy makers, and clinicians face new challenges and opportunities as precision medicine, supply chain strategies, and patient-centric models converge to improve outcomes in this specialized field.

Market Snapshot: Rare Autoinflammatory Disorders

The rare autoinflammatory disorders therapeutics market is undergoing significant transformation, driven by breakthroughs in molecular biology and a heightened focus on individualized care. Companies across regions are leveraging evolving regulatory frameworks and data-driven decision-making to expand the reach of next-generation treatments. The market's current trajectory reflects a strong commitment to patient access, operational excellence, and clinical innovation, setting the stage for sustained growth and competitive differentiation.

Scope & Segmentation

  • Indications: Cryopyrin-Associated Periodic Syndromes, including Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, and Neonatal-Onset Multisystem Inflammatory Disease; Familial Mediterranean Fever; Hyperimmunoglobulin D Syndrome; Tumor Necrosis Factor Receptor Associated Periodic Syndrome.
  • Drug Classes: Biologics (IL-1, IL-6, and TNF Inhibitors); Corticosteroids; Small Molecule Inhibitors.
  • Routes of Administration: Intravenous, Oral, Subcutaneous.
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
  • End Users: Adult, Geriatric, Pediatric patient cohorts.
  • Geographic Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Technologies: Molecular diagnostics, high-throughput screening, CRISPR-based disease models, wearable digital health monitors, artificial intelligence platforms for longitudinal data analysis.
  • Featured Companies: Takeda Pharmaceutical Company Limited, CSL Behring GmbH, Novartis AG, Swedish Orphan Biovitrum AB, Regeneron Pharmaceuticals, Inc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc.

Key Takeaways

  • Advances in genetic testing and the use of biomarkers are enabling more precise diagnosis and individualized treatment protocols for rare autoinflammatory syndromes.
  • Biologics, particularly those targeting key inflammatory pathways, play a pivotal role in disease management, with oral and subcutaneous options supporting improved patient convenience and compliance.
  • Digital health tools, including remote monitoring and telemedicine, are extending specialized care to remote and underserved regions, while supporting ongoing patient engagement and data collection.
  • Collaborative efforts across research consortia and patient registries are accelerating real-world evidence generation, supporting faster regulatory approvals and robust post-marketing surveillance.
  • Regional variation in access to therapies and reimbursement strategies requires market participants to design locally attuned entry plans and build alliances with stakeholders to optimize treatment availability.
  • The integration of value-based contracting and adaptive regulatory pathways is reshaping commercial models, aligning reimbursement more closely to real-world patient outcomes rather than traditional fixed-duration therapies.

Tariff Impact on Supply Chains

Current and upcoming United States tariff policies are prompting industry participants to reassess sourcing and contract strategies. Increased import duties on key raw materials for biologics and small molecules may trigger shifts in manufacturing localization, investment in domestic facilities, and the establishment of partnerships in tariff-exempt zones. Proactive industry engagement with regulators and trade bodies is necessary to navigate classification and exemption regulations and protect supply continuity. Inventory strategies, such as strategic stockpiling and staggered procurement, are further mitigating the effect of supply disruptions on patient care.

Methodology & Data Sources

This research applies a rigorous blend of primary interviews with clinicians, regulators, and patient organization leaders alongside a systematic secondary analysis of peer-reviewed literature, regulatory filings, trials, and patent databases. Analytical frameworks, including scenario analysis and value chain mapping, provide a robust, triangulated view of market dynamics. An advisory panel validates all findings to ensure accuracy and minimize bias.

Why This Report Matters for Rare Autoinflammatory Disorders

  • Enables senior decision-makers to benchmark global competitive strategies, operational models, and regulatory approaches relevant to the rare autoinflammatory therapeutics market.
  • Provides actionable segmentation and regional insights to guide prioritization of investment, alliance building, and patient engagement strategy.
  • Informs supply chain, reimbursement, and market access decisions with analysis of technological, policy, and patient-driven trends.

Conclusion

The rare autoinflammatory disorders therapeutic landscape is poised for transformation through scientific innovation, integrated care models, and robust data infrastructure. Stakeholders who adopt adaptive strategies while advancing patient-centric outcomes will be positioned for leadership as the market evolves.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging IL-1 and IL-18 targeted biologics showing differentiation in efficacy and safety profiles
5.2. Development of gene therapies utilizing AAV vectors for monogenic autoinflammatory disease correction
5.3. Increasing adoption of real-world evidence and patient registries to inform treatment value assessment
5.4. Expansion of precision medicine approaches based on inflammasome gene variant profiling guiding therapy selection
5.5. Growing interest in oral JAK inhibitor formulations to improve adherence in chronic autoinflammatory conditions
5.6. Integration of digital health platforms for remote monitoring and patient-reported outcomes in clinical trials
5.7. Evolution of value-based contracting models with payers for high-cost autoinflammatory disease therapeutics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Rare Autoinflammatory Diseases Drug Market, by Indication
8.1. Introduction
8.2. Cryopyrin-Associated Periodic Syndromes
8.2.1. Familial Cold Autoinflammatory Syndrome
8.2.2. Muckle-Wells Syndrome
8.2.3. Neonatal-Onset Multisystem Inflammatory Disease
8.3. Familial Mediterranean Fever
8.4. Hyperimmunoglobulin D Syndrome
8.5. Tumor Necrosis Factor Receptor Associated Periodic Syndrome
9. Rare Autoinflammatory Diseases Drug Market, by Drug Class
9.1. Introduction
9.2. Biologics
9.2.1. Il-1 Inhibitors
9.2.2. Il-6 Inhibitors
9.2.3. Tnf Inhibitors
9.3. Corticosteroids
9.4. Small Molecule Inhibitors
10. Rare Autoinflammatory Diseases Drug Market, by Route of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Rare Autoinflammatory Diseases Drug Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Rare Autoinflammatory Diseases Drug Market, by End User
12.1. Introduction
12.2. Adult Patients
12.3. Geriatric Patients
12.4. Pediatric Patients
13. Americas Rare Autoinflammatory Diseases Drug Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Rare Autoinflammatory Diseases Drug Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Rare Autoinflammatory Diseases Drug Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Takeda Pharmaceutical Company Limited
16.3.2. CSL Behring GmbH
16.3.3. Novartis AG
16.3.4. Swedish Orphan Biovitrum AB
16.3.5. Regeneron Pharmaceuticals, Inc.
16.3.6. Pharming Group N.V.
16.3.7. BioCryst Pharmaceuticals, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. RARE AUTOINFLAMMATORY DISEASES DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. RARE AUTOINFLAMMATORY DISEASES DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. RARE AUTOINFLAMMATORY DISEASES DRUG MARKET: RESEARCHAI
FIGURE 26. RARE AUTOINFLAMMATORY DISEASES DRUG MARKET: RESEARCHSTATISTICS
FIGURE 27. RARE AUTOINFLAMMATORY DISEASES DRUG MARKET: RESEARCHCONTACTS
FIGURE 28. RARE AUTOINFLAMMATORY DISEASES DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HYPERIMMUNOGLOBULIN D SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HYPERIMMUNOGLOBULIN D SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 102. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 103. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 106. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 107. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. CANADA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 114. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 115. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 116. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 117. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 118. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 119. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 120. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 121. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. MEXICO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 188. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 189. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 190. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 191. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 192. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 193. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. GERMANY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 202. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 203. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 204. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 205. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 206. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 207. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. FRANCE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 230. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 231. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 232. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 233. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 234. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 235. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. ITALY RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 242. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 243. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 244. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 245. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 246. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 247. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 248. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 249. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SPAIN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 20

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Rare Autoinflammatory Diseases Drug market report include:
  • Takeda Pharmaceutical Company Limited
  • CSL Behring GmbH
  • Novartis AG
  • Swedish Orphan Biovitrum AB
  • Regeneron Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • BioCryst Pharmaceuticals, Inc.

Related Topics

Related Reports

Periodic Fever Syndrome - Global Strategic Business Report - Product Image

Periodic Fever Syndrome - Global Strategic Business Report

  • Report
  • 390 Pages
  • Global
From
Systemic Autoinflammatory Diseases Drug Market - Global Forecast 2025-2030 - Product Image

Systemic Autoinflammatory Diseases Drug Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Anakinra Market Report 2025 - Product Image

Anakinra Market Report 2025

  • Report
  • 250 Pages
  • Global
From
IL-1 Receptor Antagonist Market - Global Forecast 2025-2030 - Product Image

IL-1 Receptor Antagonist Market - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Cryoprin-Associated Periodic Syndrome - Pipeline Insight, 2025 - Product Image

Cryoprin-Associated Periodic Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • 40 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.